{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T04:08:50Z","timestamp":1750133330964,"version":"3.41.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.lungcan.2025.108479","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:17:35Z","timestamp":1741191455000},"page":"108479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy of EGFR tyrosine kinase inhibitors in patients with non\u2013small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)"],"prefix":"10.1016","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8047-8730","authenticated-orcid":false,"given":"Yuji","family":"Uehara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-4859","authenticated-orcid":false,"given":"Hiroki","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikei S.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9627-5401","authenticated-orcid":false,"given":"Shingo","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3849-5905","authenticated-orcid":false,"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takae","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1000-0077","authenticated-orcid":false,"given":"Jun","family":"Sugisaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Takase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kageaki","family":"Taima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2365-144X","authenticated-orcid":false,"given":"Shuhei","family":"Teranishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7094-8559","authenticated-orcid":false,"given":"Shingo","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7918-7282","authenticated-orcid":false,"given":"Chiho","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8293-3992","authenticated-orcid":false,"given":"Shuichi","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Oi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hibiki","family":"Udagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaname","family":"Nosaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Zenke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-357X","authenticated-orcid":false,"given":"Kiyotaka","family":"Yoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadakatsu","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0689-395X","authenticated-orcid":false,"given":"Daniel B.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu S","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3023-2510","authenticated-orcid":false,"given":"Koichi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108479_b0005","article-title":"Real-world outcomes of treatment strategy between first-line osimertinib, first\/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC","volume":"5","author":"Uehara","year":"2024","journal-title":"ESMO Real World Data Digit. Oncol."},{"key":"10.1016\/j.lungcan.2025.108479_b0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108479_b0015","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in Resected EGFR-Mutated Non\u2013Small-Cell Lung Cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108479_b0020","article-title":"Solid predominant histology and high podoplanin expression in cancer-associated fibroblast predict primary resistance to osimertinib in EGFR-mutated lung adenocarcinoma","author":"Uehara","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2025.108479_b0025","doi-asserted-by":"crossref","DOI":"10.21037\/actr-24-7","article-title":"The Butterfly effect\u2014will the MARIPOSA-2 study alter the trajectory of EGFR mutated non-small cell lung cancer (NSCLC)","volume":"2","author":"Uehara","year":"2024","journal-title":"AME Clin. Trials Rev."},{"key":"10.1016\/j.lungcan.2025.108479_b0030","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2025.108479_b0035","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2025.108479_b0040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108479_b0045","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108479_b0050","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol. off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108479_b0055","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ccell.2022.06.006","article-title":"Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity","volume":"40","author":"Elamin","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2025.108479_b0060","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20\u2013selective kinase inhibitor in non\u2013small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2025.108479_b0065","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.00152","article-title":"Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non\u2013Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions","volume":"41","author":"Piotrowska","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108479_b0070","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1200\/JCO.23.00958","article-title":"Zipalertinib in EGFR Exon 20\u2013Mutant Non\u2013Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting","volume":"41","author":"Aggarwal","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108479_b0075","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/2159-8290.CD-21-1615","article-title":"Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations","volume":"12","author":"Wang","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2025.108479_b0080","first-page":"e107","article-title":"An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment","author":"Chan","year":"2013","journal-title":"J. Thorac. Oncol. off. Publ. Int. Assoc. Study Lung Cancer 8"},{"key":"10.1016\/j.lungcan.2025.108479_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107250","article-title":"EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors","volume":"181","author":"Shaffer","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108479_b0090","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1158\/1078-0432.CCR-11-2361","article-title":"EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma","volume":"18","author":"He","year":"2012","journal-title":"Clin. Cancer Res. off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108479_b0095","doi-asserted-by":"crossref","first-page":"111246","DOI":"10.18632\/oncotarget.22768","article-title":"Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients","volume":"8","author":"Su","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2025.108479_b0100","first-page":"1895","article-title":"Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations","author":"De Pas","year":"2011","journal-title":"J. Thorac. Oncol. off. Publ. Int. Assoc. Study Lung Cancer 6"},{"key":"10.1016\/j.lungcan.2025.108479_b0105","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cllc.2016.12.014","article-title":"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer","volume":"18","author":"Lin","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108479_b0110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.lungcan.2022.12.019","article-title":"Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study","volume":"176","author":"Tamiya","year":"2023","journal-title":"Lung Cancer Amst. Neth."},{"key":"10.1016\/j.lungcan.2025.108479_b0115","article-title":"Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia, Lung Cancer Amst","volume":"191","author":"Okahisa","year":"2024","journal-title":"Neth."},{"key":"10.1016\/j.lungcan.2025.108479_b0120","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jtho.2023.07.024","article-title":"Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia)","volume":"18","author":"Sakai","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108479_b0125","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41586-021-04135-5","article-title":"The CLIP1-LTK fusion is an oncogenic driverin non-small-cell lung cancer","volume":"600","author":"Izumi","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2025.108479_b0130","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-22-1749","article-title":"A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non\u2013Small Cell Lung Cancer (LC-SCRUM-Liquid)","volume":"29","author":"Sugimoto","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108479_b0135","article-title":"Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib","author":"Umemura","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108479_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107992","article-title":"Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia","volume":"197","author":"Kato","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108479_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107190","article-title":"Clinical application of the AMOY 9-in-1 panel to lung cancer patients","volume":"179","author":"Kunimasa","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108479_b0150","article-title":"Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations","volume":"2","author":"Vasconcelos","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2025.108479_b0155","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.1158\/1078-0432.CCR-18-1541","article-title":"20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas","volume":"24","author":"Jorge","year":"2018","journal-title":"Clin. Cancer Res. off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108479_b0160","article-title":"EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors","volume":"1","author":"Vasconcelos","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2025.108479_b0165","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.3390\/cells10123561","article-title":"EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios","volume":"10","author":"Kobayashi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.lungcan.2025.108479_b0170","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41597-024-03327-8","article-title":"Analysis of AlphaMissense data in different protein groups and structural context","volume":"11","author":"Tordai","year":"2024","journal-title":"Sci. Data"},{"key":"10.1016\/j.lungcan.2025.108479_b0175","doi-asserted-by":"crossref","unstructured":"J. Cheng G. Novati J. Pan C. Bycroft A. \u017demgulyt\u0117 T. Applebaum A. Pritzel L.H. Wong M. Zielinski T. Sargeant R.G. Schneider A.W. Senior J. Jumper D. Hassabis P. Kohli \u017d. Avsec Accurate proteome-wide missense variant effect prediction with AlphaMissense, Science 381 2023 10.1126\/science.adg7492 eadg7492.","DOI":"10.1126\/science.adg7492"},{"key":"10.1016\/j.lungcan.2025.108479_b0180","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","article-title":"ColabFold: making protein folding accessible to all","volume":"19","author":"Mirdita","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.lungcan.2025.108479_b0185","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2025.108479_b0190","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2105-10-32","article-title":"VASCo: computation and visualization of annotated protein surface contacts","volume":"10","author":"Steinkellner","year":"2009","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.lungcan.2025.108479_b0195","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1472-6807-6-19","article-title":"LIGSITEcsc: predicting ligand binding sites using the Connolly surface and degree of conservation","volume":"6","author":"Huang","year":"2006","journal-title":"BMC Struct. Biol."},{"key":"10.1016\/j.lungcan.2025.108479_b0200","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/j.seminoncol.2019.08.004","article-title":"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib","volume":"46","author":"Masood","year":"2019","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108479_b0205","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022500371X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022500371X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T23:45:00Z","timestamp":1750117500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022500371X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":41,"alternative-id":["S016950022500371X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108479","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of EGFR tyrosine kinase inhibitors in patients with non\u2013small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108479"}}